Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
Celcuity Inc. (Nasdaq:CELC) will release its Q2 2021 financial results on August 9, 2021, after market close. A teleconference is scheduled for 4:30 p.m. Eastern Time on the same day to discuss the results. Celcuity focuses on cancer treatment through an integrated companion diagnostic and therapeutic strategy. Its CELsignia platform analyzes live tumor cells to identify cancer patients who may benefit from targeted therapies. For participation, dial 844-369-8770 (domestic) or 862-298-0840 (international).
- The upcoming release of Q2 2021 financial results may indicate progress in business development.
- Celcuity's CELsignia platform offers unique capabilities that may attract investor interest.
- As a clinical-stage company, there is inherent risk associated with product development timelines.
MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the second quarter 2021 after the stock market close on Monday, August 9, 2021. Management will host a teleconference the same day at 4:30 p.m. Eastern Time to discuss the results.
Webcast and Conference Call Information
The Celcuity management team will host a webcast/conference call on August 9, 2021, at 4:30 p.m. ET. To participate in the call, dial 844-369-8770 for domestic callers and 862-298-0840 for international callers. A live webcast of the call can be accessed using this weblink at: https://www.webcaster4.com/Webcast/Page/2678/42136. A replay of the webcast will be available on the Celcuity website following the event.
About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic and therapeutic strategy. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Its therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
Westwicke ICR
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886
SOURCE: Celcuity Inc.
View source version on accesswire.com:
https://www.accesswire.com/657957/Celcuity-Inc-Schedules-Release-of-Second-Quarter-2021-Financial-Results-and-Webcast
FAQ
When will Celcuity release its Q2 2021 financial results?
What is the purpose of the Celcuity conference call on August 9, 2021?
How can I access the Celcuity conference call?
What does Celcuity do?
